Trever G. Bivona Department of Medicine University of California, San Francisco Biography Publications Institution JoVE Articles Trever G. Bivona has not added a biography. If you are Trever G. Bivona and would like to personalize this page please email our Author Liaison for assistance. Publications Exocyst Protein Subnetworks Integrate Hippo and MTOR Signaling to Promote Virus Detection and Cancer Cell Reports. Aug, 2021 | Pubmed ID: 34348154 Stepwise Evolution of Therapy Resistance in AML Cancer Cell. Jul, 2021 | Pubmed ID: 34171262 Kinase-mediated RAS Signaling Via Membraneless Cytoplasmic Protein Granules Cell. May, 2021 | Pubmed ID: 33848463 Single-cell Lineages Reveal the Rates, Routes, and Drivers of Metastasis in Cancer Xenografts Science (New York, N.Y.). 02, 2021 | Pubmed ID: 33479121 Allosteric SHP2 Inhibitors in Cancer: Targeting the Intersection of RAS, Resistance, and the Immune Microenvironment Current Opinion in Chemical Biology. 06, 2021 | Pubmed ID: 33418513 Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing Cell. 09, 2020 | Pubmed ID: 32822576 Multi-faceted Epigenetic Dysregulation of Gene Expression Promotes Esophageal Squamous Cell Carcinoma Nature Communications. 07, 2020 | Pubmed ID: 32699215 Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 01, 2020 | Pubmed ID: 31548343 Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale Cancers. Sep, 2019 | Pubmed ID: 31533235 Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers Cell Reports. 08, 2019 | Pubmed ID: 31461649 Targeting Oncogenic BRAF: Past, Present, and Future Cancers. Aug, 2019 | Pubmed ID: 31426419 Engineering Multidimensional Evolutionary Forces to Combat Cancer Cancer Discovery. 05, 2019 | Pubmed ID: 30992280 Dampening Oncogenic RAS Signaling Science (New York, N.Y.). 03, 2019 | Pubmed ID: 30898918 Polytherapy and Targeted Cancer Drug Resistance Trends in Cancer. 03, 2019 | Pubmed ID: 30898264 Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer Current Oncology Reports. 02, 2019 | Pubmed ID: 30806814 Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology Trends in Molecular Medicine. 03, 2019 | Pubmed ID: 30686761 Immunohistochemistry to Study YAP in Human Tissue Samples Methods in Molecular Biology (Clifton, N.J.). 2019 | Pubmed ID: 30565127 Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins Cancer Research. 02, 2019 | Pubmed ID: 30538120 Cancer Mutations and Targeted Drugs Can Disrupt Dynamic Signal Encoding by the Ras-Erk Pathway Science (New York, N.Y.). 08, 2018 | Pubmed ID: 30166458 RAS Nucleotide Cycling Underlies the SHP2 Phosphatase Dependence of Mutant BRAF-, NF1- and RAS-driven Cancers Nature Cell Biology. 09, 2018 | Pubmed ID: 30104724 Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids Dora Barbosa Rabago1,2,3, Collin M. Blakely1,2, Franziska Haderk1,2,3, Trever G. Bivona1,2,3 1Department of Medicine, University of California, San Francisco, 2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 3Department of Cellular and Molecular Pharmacology, University of California, San Francisco JoVE 63039 Cancer Research
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids Dora Barbosa Rabago1,2,3, Collin M. Blakely1,2, Franziska Haderk1,2,3, Trever G. Bivona1,2,3 1Department of Medicine, University of California, San Francisco, 2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 3Department of Cellular and Molecular Pharmacology, University of California, San Francisco JoVE 63039 Cancer Research
